Advertisement
MDT vs SYK
Which Stock Would AI Choose? Medtronic (MDT) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Both MDT and SYK operate in the medical devices sector and have traded near 52-week lows amid broader healthcare market pressures in recent market activity.
- Medtronic reported its strongest annual revenue growth in a decade for fiscal 2026, with worldwide revenue reaching $36.4 billion.
- Stryker posted modest Q1 2026 sales growth of 2.6% and faces its Q2 earnings report later in July 2026, with analysts expecting an 11.5% rise in adjusted EPS.
- MDT currently offers a higher dividend yield compared with SYK, while SYK has historically demonstrated stronger long-term performance in robotics and select surgical segments.
- Recent sector headwinds, including index adjustments for SYK and a product recall for MDT, have influenced short-term sentiment for both stocks.
- Analyst price targets remain above current levels for both names, reflecting expectations of recovery in the medical technology space.
Introduction
Medtronic (MDT) and Stryker (SYK) represent two leading players in the global medical devices industry, making them natural candidates for comparison among investors seeking exposure to healthcare innovation. Both companies develop and market technologies used in hospitals and surgical settings, yet they differ in product focus, growth profiles, and recent financial momentum. This comparison is particularly relevant for portfolio managers, sector-focused traders, and long-term investors evaluating relative positioning within the medical technology space during periods of market volatility and evolving healthcare demand.
MDT Overview and Recent Performance
Medtronic is a diversified medical technology company offering products across cardiovascular, diabetes, neuroscience, and surgical technologies. In recent market activity, the stock has traded near the lower end of its 52-week range following broader sector pressures, with a recent closing price around $82. Despite a year-to-date decline, the company delivered its highest annual revenue growth in ten years for fiscal 2026, reporting worldwide revenue of $36.4 billion, up 8.4% as reported. The June earnings release highlighted strong Q4 performance with revenue growth exceeding guidance. Sentiment has been tempered by a voluntary Class II recall of a tissue stabilizer product, though analysts maintain generally positive outlooks with average price targets well above current levels.
SYK Overview and Recent Performance
Stryker specializes in orthopedic implants, surgical equipment, neurotechnology, and medical devices, with growing emphasis on robotics-assisted procedures. In recent market activity, the stock has also operated near the lower portion of its 52-week range amid healthcare sector rotation, recently closing around $327. The company reported first-quarter 2026 net sales of $6.02 billion, reflecting 2.6% year-over-year growth, while maintaining full-year organic sales guidance. Upcoming second-quarter results scheduled for late July are anticipated to show continued earnings expansion. External factors including removal from certain Russell growth indices and operational impacts from a cyber incident have contributed to near-term volatility, though active investor interest has been noted ahead of earnings.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots drawn from hundreds available across thousands of tickers. Only the strongest strategies suited to prevailing market conditions earn placement in this section, reflecting rigorous performance filtering. Available bots span diverse trading styles, strategies, timeframes, and ticker sets, with historical win rates, profit factors, and drawdown statistics varying widely depending on the specific algorithm. This resource allows traders to explore data-driven approaches tailored to individual risk preferences and market environments. For additional details, visit the Trending AI Robots page.
Head-to-Head Comparison
Medtronic maintains a broader product portfolio spanning multiple therapeutic areas, while Stryker concentrates more heavily on orthopedics, spine, and surgical technologies with notable robotics exposure. Growth drivers differ accordingly: MDT benefited from robust recent revenue acceleration in cardiovascular and diabetes segments, whereas SYK has historically leveraged procedural volume recovery and innovation in minimally invasive solutions. Recent momentum favors MDT following its fiscal 2026 earnings beat, though SYK offers a longer track record of superior multi-year returns in certain segments. Risk factors include regulatory and product liability exposure for both, with MDT carrying a higher dividend yield as a potential buffer. Market sentiment remains cautious across the sector, with both stocks reflecting sensitivity to macroeconomic and healthcare policy developments.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, revenue trajectory, and relative stability in the current environment, Tickeron’s AI models would currently assign a higher probability of favorable positioning to MDT. The company’s demonstrated fiscal 2026 growth outperformance and analyst support provide a more constructive near-term signal compared with SYK’s more measured Q1 results and upcoming earnings catalyst. This assessment remains probabilistic and subject to evolving market data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDT is a Hold and SYK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDT’s FA Score shows that 1 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- MDT’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDT’s TA Score shows that 4 TA indicator(s) are bullish while SYK’s TA Score has 4 bullish TA indicator(s).
- MDT’s TA Score: 4 bullish, 4 bearish.
- SYK’s TA Score: 4 bullish, 6 bearish.
Price Growth
MDT (@Medical/Nursing Services) experienced а -5.40% price change this week, while SYK (@Medical/Nursing Services) price change was -5.66% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.71%. For the same industry, the average monthly price growth was -0.96%, and the average quarterly price growth was -16.83%.
Reported Earning Dates
MDT is expected to report earnings on Aug 25, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.71% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| MDT | SYK | MDT / SYK | |
| Capitalization | 103B | 121B | 85% |
| EBITDA | 9.81B | 6.44B | 152% |
| Gain YTD | -16.022 | -11.018 | 145% |
| P/E Ratio | 21.57 | 36.63 | 59% |
| Revenue | 36.4B | 25.3B | 144% |
| Total Cash | 9.22B | N/A | - |
| Total Debt | 28B | 14.7B | 190% |
MDT | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 66 | |
SMR RATING 1..100 | 72 | 57 | |
PRICE GROWTH RATING 1..100 | 58 | 57 | |
P/E GROWTH RATING 1..100 | 66 | 82 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (3) in the Medical Specialties industry is in the same range as SYK (9). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (66) in the Medical Specialties industry is somewhat better than the same rating for MDT (100). This means that SYK’s stock grew somewhat faster than MDT’s over the last 12 months.
SYK's SMR Rating (57) in the Medical Specialties industry is in the same range as MDT (72). This means that SYK’s stock grew similarly to MDT’s over the last 12 months.
SYK's Price Growth Rating (57) in the Medical Specialties industry is in the same range as MDT (58). This means that SYK’s stock grew similarly to MDT’s over the last 12 months.
MDT's P/E Growth Rating (66) in the Medical Specialties industry is in the same range as SYK (82). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
| MDT | SYK | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 54% |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 49% | 2 days ago 57% |
| MACD ODDS (%) | N/A | 2 days ago 51% |
| TrendWeek ODDS (%) | 2 days ago 56% | 2 days ago 52% |
| TrendMonth ODDS (%) | 2 days ago 54% | 2 days ago 47% |
| Advances ODDS (%) | 6 days ago 52% | 3 days ago 56% |
| Declines ODDS (%) | 2 days ago 57% | 15 days ago 53% |
| BollingerBands ODDS (%) | 2 days ago 45% | 2 days ago 45% |
| Aroon ODDS (%) | 2 days ago 30% | 2 days ago 45% |
Advertisement
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.